- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- Analysis
- Focus Articles
- Related Articles1 new
- Instablogs
- StockTalks
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
PDLI Market Currents
more »
-
May 3 PDL BioPharma (PDLI): Q1 EPS of $0.29 beats by $0.02. Revenue of $77.3M (-7.2% Y/Y) in-line. (PR)
Comment![Earnings, Healthcare]
PDLI Related Articles
more »
PDLI News
more »
-
at MarketWatch.com (Jan 6, 2012)
-
at CNBC.com (Aug 15, 2011)
-
at MarketWatch.com (Jul 11, 2011)
-
at MarketWatch.com (Jul 11, 2011)
-
at CNBC.com (Mar 8, 2011)
PDLI Press Releases and Filings
more »
-
PR Newswire (May 8, 2012)
-
PR Newswire (May 3, 2012)
-
PR Newswire (Apr 27, 2012)
-
PR Newswire (Apr 26, 2012)
-
PR Newswire (Apr 12, 2012)
PDLI Latest Transcript
more »
-
Thu, May 3Popular searches: intermune.
PDLI Cramer
more »
-
Thu, Apr 7, 2011
-
Wed, Mar 9, 2011
-
Tue, Mar 8, 2011
PDLI Instablog posts
more »
PDLI vs. ETF Alternatives
Company Description
We were organized as a Delaware corporation in 1986 under the name Protein Design Labs, Inc. In 2006, we changed our name to PDL BioPharma, Inc. Our business is the management of our antibody humanization patents and royalty assets which consist of our Queen et al. patents and license agreements... More
